首页> 美国卫生研究院文献>other >Amelioration of Hyperglycemia with a Sodium-Glucose Cotransporter 2 Inhibitor Prevents Macrophage-Driven Atherosclerosis through Macrophage Foam Cell Formation Suppression in Type 1 and Type 2 Diabetic Mice
【2h】

Amelioration of Hyperglycemia with a Sodium-Glucose Cotransporter 2 Inhibitor Prevents Macrophage-Driven Atherosclerosis through Macrophage Foam Cell Formation Suppression in Type 1 and Type 2 Diabetic Mice

机译:钠-葡萄糖共转运蛋白2抑制剂改善高血糖症可通过抑制1型和2型糖尿病小鼠的巨噬细胞泡沫细胞形成来预防巨噬细胞驱动的动脉粥样硬化。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Direct associations between hyperglycemia and atherosclerosis remain unclear. We investigated the association between the amelioration of glycemia by sodium-glucose cotransporter 2 inhibitors (SGLT2is) and macrophage-driven atherosclerosis in diabetic mice. We administered dapagliflozin or ipragliflozin (1.0 mg/kg/day) for 4-weeks to apolipoprotein E-null (Apoe −/−) mice, streptozotocin-induced diabetic Apoe −/− mice, and diabetic db/db mice. We then determined aortic atherosclerosis, oxidized low-density lipoprotein (LDL)-induced foam cell formation, and related gene expression in exudate peritoneal macrophages. Dapagliflozin substantially decreased glycated hemoglobin (HbA1c) and glucose tolerance without affecting body weight, blood pressure, plasma insulin, and lipids in diabetic Apoe −/− mice. Aortic atherosclerotic lesions, atheromatous plaque size, and macrophage infiltration in the aortic root increased in diabetic Apoe −/− mice; dapagliflozin attenuated these changes by 33%, 27%, and 20%, respectively. Atherosclerotic lesions or foam cell formation highly correlated with HbA1c. Dapagliflozin did not affect atherosclerosis or plasma parameters in non-diabetic Apoe −/− mice. In db/db mice, foam cell formation increased by 4-fold compared with C57/BL6 mice, whereas ipragliflozin decreased it by 31%. Foam cell formation exhibited a strong correlation with HbA1c. Gene expression of lectin-like ox-LDL receptor-1 and acyl-coenzyme A:cholesterol acyltransferase 1 was upregulated, whereas that of ATP-binding cassette transporter A1 was downregulated in the peritoneal macrophages of both types of diabetic mice. SGLT2i normalized these gene expressions. Our study is the first to demonstrate that SGLT2i exerts anti-atherogenic effects by pure glucose lowering independent of insulin action in diabetic mice through suppressing macrophage foam cell formation, suggesting that foam cell formation is highly sensitive to glycemia ex vivo.
机译:高血糖与动脉粥样硬化之间的直接关联仍不清楚。我们调查了糖尿病小鼠中钠-葡萄糖共转运蛋白2抑制剂(SGLT2is)改善血糖与巨噬细胞驱动的动脉粥样硬化之间的关联。我们对载脂蛋白E-null(Apoe -/-)小鼠,链脲佐菌素诱导的糖尿病Apoe -/-给予达格列净或伊格列净(1.0 mg / kg /天)4周。 sup>小鼠和糖尿病db / db小鼠。然后,我们确定了主动脉粥样硬化,氧化的低密度脂蛋白(LDL)诱导的泡沫细胞形成,以及渗出性腹膜巨噬细胞中的相关基因表达。达格列净可显着降低糖化血红蛋白(HbA1c)和葡萄糖耐量,而不会影响糖尿病Apoe -/-小鼠的体重,血压,血浆胰岛素和脂质。糖尿病Apoe -/-小鼠的主动脉粥样硬化病变,动脉粥样斑块大小和主动脉根部巨噬细胞浸润增加;达格列净使这些变化分别减少了33%,27%和20%。动脉粥样硬化病变或泡沫细胞形成与HbA1c高度相关。 Dapagliflozin不会影响非糖尿病Apoe -/-小鼠的动脉粥样硬化或血浆参数。在db / db小鼠中,与C57 / BL6小鼠相比,泡沫细胞形成增加了4倍,而伊普列净则使泡沫细胞形成减少了31%。泡沫细胞的形成与HbA1c密切相关。在两种类型的糖尿病小鼠的腹膜巨噬细胞中,凝集素样ox-LDL受体-1和酰基辅酶A:胆固醇酰基转移酶1的基因表达上调,而ATP结合盒转运蛋白A1的基因表达下调。 SGLT2i使这些基因表达正常化。我们的研究首次证明SGLT2i通过抑制巨噬细胞泡沫细胞的形成,通过纯葡萄糖降低糖尿病小鼠的胰岛素作用而发挥抗动脉粥样硬化作用,这表明泡沫细胞的形成对离体血糖高度敏感。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号